Zacks Investment Research cut shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a sell rating in a research report report published on Tuesday.
According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
CAPR has been the topic of a number of other research reports. TheStreet lowered Capricor Therapeutics from a c- rating to a d+ rating in a research note on Monday, October 15th. Maxim Group restated a buy rating and set a $4.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, November 14th. HC Wainwright restated a buy rating and set a $9.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday, November 20th. Finally, ValuEngine lowered Capricor Therapeutics from a hold rating to a sell rating in a research note on Friday, December 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $3.00.
Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Tuesday, November 13th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.01). The firm had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.90 million. Capricor Therapeutics had a negative return on equity of 159.36% and a net margin of 24.75%. On average, research analysts predict that Capricor Therapeutics will post -0.57 earnings per share for the current fiscal year.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.